Abdera Therapeutics is a precision oncology company focused on developing next-generation targeted radiation therapies. Utilizing their proprietary ROVEr™ platform, they aim to deliver radioisotopes that selectively destroy tumor cells while sparing healthy cells. The company is building a pipeline of innovative radiotherapeutics targeting various solid tumors, with plans to initiate Phase 1 clinical trials for small cell lung cancer and large cell neuroendocrine carcinoma. Abdera's unique approach and advanced technology position it as a leader in the rapidly evolving field of radiotherapeutics, addressing significant unmet needs in cancer treatment.

Ability Biologics is a leading biotherapeutic targeting company focused on developing innovative, immune-modulating biotherapeutics to address unmet medical needs in cancer and autoimmune diseases. Utilizing their proprietary Abi Leap™ discovery engine, they produce fully human, Ig G-based multispecific antibodies with exceptional selectivity and affinity. Their technology leverages artificial intelligence and a vast database of antigen-antibody interactions to create highly specific therapeutics. The company is dedicated to advancing preclinical antibody candidates and aims to conduct human proof of concept clinical trials, positioning itself as a key player in the biotherapeutics market.

Amplitude Venture Capital deploys a growth model that has successfully been used to build Canadian companies with world-class management teams and scale companies to breakout potential. Since 2012 Amplitude's founding team has raised over $700 million of equity capital in private and public markets. Amplitude, with offices in Montreal, Toronto, and Vancouver, launched its first private capital fund in November 2019, a $200-million fund that applies a proven, evidence-based approach to investing in leading Canadian precision medicine companies.

Congruence Therapeutics is a drug discovery company that leverages protein dynamics, biophysics, machine learning, and computational chemistry to create predictive models for drug design. Their innovative Revenir™ Product Engine allows for the visualization of proteins in their dynamic states, enabling the design of small molecules aimed at treating diseases caused by protein misfolding. With a focus on high unmet medical needs, Congruence is positioned to transform drug discovery and improve patient outcomes.

Deep Genomics is an AI-driven genetic medicine company that focuses on programming RNA therapies for any gene and genetic condition. Their proprietary AI platform, Big RNA, enables the discovery of novel therapeutic candidates by untangling the complexities of RNA biology. With a strong interdisciplinary team of over 100 experts, they have made significant advancements in RNA therapeutic development, including the release of the first Foundation Model for RNA Biology. The company is positioned at the forefront of drug development, leveraging AI to address complex genetic diseases and has received recognition as a leading biotechnology company.

DrugBank augments human intelligence to improve the world’s health. Our suite of products are powered by the world’s most complete and up-to-date pharmaceutical knowledge database. It includes everything there is to know about drugs and how they work in the body. We enable companies to improve healthcare delivery through precision medicine or clinical software applications, as well as uncover insights through data science in drug discovery. Our knowledge base can be integrated into software solutions to help achieve clinical intelligence. Companies can easily scale their usage through our API and launch faster with flexible data modules. By providing users with advanced insights and the right information at the right time, users are empowered to make better health decisions. Our extensive, structured datasets are used to discover novel drug candidates, identify drug repurposing opportunities, and build predictive machine learning models. Companies working with data science can find answers quickly and get drugs to market faster with our evidence-based drug information. Lastly, our publicly available resource, DrugBank Online, is free-to-use with limited datasets available for download for academic and non-commercial researchers. DrugBank has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.

Evommune is focused on discovering and developing novel therapies for chronic inflammatory diseases, targeting the root causes of inflammation with a robust pipeline that includes the MRGPRX2 Antagonist, IL-18 Fusion Protein, and PKCθ Inhibitor. The company aims to address the high unmet needs in underserved patient populations, leveraging extensive R&D expertise in immunology to deliver therapeutics that go beyond symptomatic relief. With a commitment to advancing clinical-stage pipelines, Evommune is positioned to make significant impacts in the treatment of chronic inflammatory diseases, which are increasingly recognized as a global health crisis.

Gandeeva Therapeutics is a precision biotechnology company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva’s structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline targeting difficult-to-treat cancers with novel protein interaction modulators such as interfacial glues (iGlues™) and allosteric inhibitors. Gandeeva is headquartered in the Greater Vancouver area, Canada. Please visit www.gandeeva.com or follow us on LinkedIn and Twitter for more information.

Nomic is a bioengineering company working to make the human proteome as broadly and easily accessible as the human genome. They are building the nELISA, a next-generation ELISA platform for measuring proteins at scale and at high throughput. They offer scientists protein profiling solutions to empower them to decide the scope and scale of their experiments.

Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells. The company's proprietary T-cell production platform enables precision control of Notch signaling, which is required for T-cell development, by combining sophisticated product design with commercial-compatible processes. The ability to control notch signaling eliminates several critical limiting factors in cell therapy development and provides the ability to design and manufacture a consistent and limitless supply of therapeutic T cells. Notch Therapeutics was established in 2018 and is headquartered in Toronto, Canada.

Prilenia is a clinical-stage biotech company founded in 2018, dedicated to developing novel therapeutics for neurodegenerative diseases such as Huntington's disease and amyotrophic lateral sclerosis (ALS). The company focuses on its lead product, Pridopidine, an oral sigma-1 receptor agonist currently in late-stage clinical development, which has an established safety profile. With a team of experienced scientists and drug developers, Prilenia aims to provide hope to patients and families affected by these conditions. The company operates globally with offices in the Netherlands, Israel, and the United States, and is backed by reputable investors, indicating strong market position and traction in the biotech sector.

Repare Therapeutics is a leading clinical-stage precision oncology company focused on synthetic lethality. Utilizing their proprietary SNIPRx® platform, they systematically discover and develop targeted cancer therapies that address genomic instability, particularly in DNA damage repair. Founded in 2016 by leading academics, the company aims to be a leader in biopharmaceuticals by developing small molecule therapies based on synthetic lethality, identifying novel targets, designing selective inhibitors, and expanding treatment options for patients with high unmet medical needs.